Graylands Hospital Drug Bulletin
|
|
- Magnus Horton
- 5 years ago
- Views:
Transcription
1 Graylands Hospital Drug Bulletin Lurasidone (Latuda ) North Metropolitan Health Service - Mental Health April 2016 Vol 23 No.1 ISSN Introduction Lurasidone is the latest antipsychotic medication to have been listed on the Pharmaceutical Benefits Scheme for the treatment of schizophrenia. It was approved for the treatment of schizophrenia in the USA in 2010, Canada in 2012 and in the UK in European Union marketing authority was granted for once daily dosing of lurasidone for schizophrenia in In 2013, the FDA also approved lurasidone for the treatment of depressive episodes in bipolar disorder. In 2015, lurasidone was ranked by Medscape as the 78 th most prescribed drug in the USA and is the third most prescribed antipsychotic behind aripiprazole and quetiapine. It is now six years since lurasidone was licenced for treatment of schizophrenia in the USA and three years since approval for bipolar treatment was granted. In preparing this drug bulletin, 56 articles were read and of those, only 12 had no drug company affiliation. Receptor Effects 1-4 D 2 Dopamine antagonist 5HT 2A antagonist 5HT 7 antagonist 5HT 1A - partial agonist Lurasidone has potent D 2 and 5-HT 2A affinity and also greater affinity than other second generation antipsychotics to 5-HT 7, 5-HT 1A and α 2c receptors. 5, 6 Lurasidone has little affinity for α 1, H 1 and M 1 receptors. The lack of α 1 affinity predicts for a lower risk of postural hypotension, the absence of 5-HT 2C, H 1 and M 1 affinity predict lurasidone will be less sedating, will not cause weight gain and will have a lower chance of causing anticholinergic effects and 1, 7, 8 4 negative cognitive effects. Despite this, there have been reports of modest sedation and dizziness and it has been proposed that these side effects may relate to as yet uncharacterized properties of potent 5HT 7 antagonism. 5 5-HT 7 has relatively recently been linked to circadian rhythm, sleep cycles, and areas of the brain implicated in mood regulation. 1 Positive effects of 5-HT 7 antagonism have been shown. Research in animal models indicates impairments of learning and memory are reversed by lurasidone. 5 The same tests using risperidone and clozapine showed only weak reversal of impairment. Preclinical lurasidone results indicate there may be advantages in the effects on cognition compared to other antipsychotics. 5 Lurasidone is expected to possess anxiolyticor antidepressant-like activity because of its higher affinities for 5-HT 7 and 5-HT 1A receptors. In terms of its receptor affinities, of the other second generation antipsychotics, lurasidone is probably most similar to risperidone and paliperidone, although there are significant Lurasidone Summary Approval : Schizophrenia Uses outside Australia: Bipolar Disorder, Depressive symptoms Recommended Dose: 40mg at night Maximum Dose : 160mg daily To be taken with food Metabolism: CYP3A4 Common Side Effects: akathisia, nausea, parkinsonism, and somnolence Availability: 40mg and 80mg filmcoated tablet Graylands Hospital Drug Bulletin April 2016 Vol 23 No.1 Page 1
2 differences to these drugs. 2 Pharmacokinetics Lurasidone is rapidly absorbed, with a time to maximum concentration of 1 to 3 hours and a mean half-life of 18 hours for a 40 mg dose. 1 However, lurasidone has poor bioavailability (approximately 20%), in part, due to extensive first pass metabolism by CYP3A4. 2, 5 Food increases the AUC of a 20mg dose threefold. 5 Lurasidone should be administered with a meal of at least 350 calories, regardless of fat content, to ensure maximum absorption. 2 Lurasidone is 99.8% protein bound with affinity to albumin and α 1-glycoprotein. 5 Lurasidone is eliminated by hepatic metabolism, primarily by CYP3A4. 2 Two of the metabolites are active but have low affinity for the human D 2 and 5-HT receptors. Two other metabolites have similar binding affinities to lurasidone but the clinical significance of these is not clear. 2, 6 The elimination half-life has been reported as being between 12.2 and 18.3 hours 2, 6 but this reflects results from single dose studies. At steady state, the half-life has been reported to increase to 36 hours. 5 This difference may explain the statement made in the product information: Steady- state concentrations of lurasidone are reached within 7 days of starting lurasidone. Following administration of 40 mg the mean elimination half-life was 18 hours. 6 It is widely accepted that steady state is reached in approximately 5 half-lives. If steady state is achieved in 7 days then the elimination half-life would have to be 33.6 hours. Renal and Hepatic Impairment No dosage adjustment is required with mild renal or hepatic impairment. In patients with moderate renal or hepatic impairment (CrCL 30 to 50 ml/min, Child-Pugh class B), the recommended starting dose is 20mg and the maximum dose should not exceed 80mg once daily. Lurasidone is not recommended in severe renal or hepatic impairment. 6 Interactions Caution is advised when combining with alcohol or CNS active medications, and medicines known to cause QT prolongation. 6 Lurasidone is mainly metabolised by CYP 3A4. The Australian, European and USA product information lists concomitant use of strong CYP 3A4 inhibitors and inducers as a contraindication. 6, 9, 10 As this is a predictable drug interaction, to include it among the strongest prohibitions seems overly cautious. The UK product information also mentions P- gp and BCRP inhibitors and gives dabigatran as an example 11 The European product information advises that lurasidone is an in vitro inhibitor of P-gp and BCRP but the clinical significance of this is unknown. 9 Lurasidone is a substrate of P-gp and BCRP in vitro but the in vivo relevance of this is unclear. Coadministration of lurasidone with P-gp and BCRP inhibitors increase exposure to lurasidone. 6, 9 Coadministration of lurasidone with digoxin (a P-gp substrate) did not increase the exposure to digoxin and only slightly increased C max (1.3 fold) and therefore, it is considered that lurasidone can be coadministered with digoxin. 6 Although the manufacturer does not recommend additional digoxin monitoring, given the narrow therapeutic index of digoxin, it may be prudent to monitor digoxin concentrations after the initiation of lurasidone. 12 Concomitant administration of the P-gp substrate dabigatran etexilate may result in increased dabigatran plasma concentrations. 9 Adverse Effects The various location versions of product information (PI) for Latuda contain much the same information in greater or lesser detail. The adverse events can be grouped into those which are mentioned in the PI but have little supporting evidence and those that are mentioned and have evidence indicating they are likely to occur. Graylands Hospital Drug Bulletin April 2016 Vol 23 No.1 Page 2
3 Adverse Events with Little Supporting Evidence Leucopenia, neutropenia and agranulocytosis The product information carries a warning against these blood dyscrasias but refers to reports during treatment with antipsychotic agents and other agents in the same class. 6 Conversation and correspondence with the Servier drug information service did not reveal any case reports of lurasidone being associated with blood dyscrasias and Servier ultimately referred questions on this topic back to the product information. Based on this, it seems that the warning is based on class effects alone and there appears to be no particular concern with lurasidone having the tendency to cause leucopenia, neutropenia or agranulocytosis. QTc Prolongation Phase II studies indicate lurasidone causes no significant QTc prolongation. 5 The product information, however, recommends caution when LATUDA is prescribed in patients with known cardiovascular disease or family history of QT prolongation, hypokalaemia, and in concomitant use with other medicinal products thought to prolong the QT interval. 6 A review article comparing 15 antipsychotics also found that lurasidone was the only antipsychotic with less QTc prolongation than placebo. 13 Seizure Frequency A warning to use lurasidone cautiously in patients with seizures is present in the product information. 6 However, lurasidone was not associated with increased seizure frequency in Phase II trials, nor was there any reported significant change in EEG. 5 Metabolic Profile Lurasidone has been reported to have little metabolic effects with negligible weight gain, dyslipidaemia and changes to glucose control. 5 A pooled analysis of lurasidone effects on weight and BMI changes showed that lurasidone has a lower liability for long term weight gain than other atypical antipsychotics. 14 Orthostatic Hypotension A warning that lurasidone may cause orthostatic hypotension is present in the product information. 6, 10 However, these statements combine dizziness, tachycardia and orthostatic hypotension. Macaluso et al in a review state that Supporting evidence for adrenergic blockade can be extrapolated from the fact that cases of orthostatic hypotension were reported in the clinical trials of lurasidone. 2 but they do not reference supporting evidence. Most literature does not mention orthostatic hypotension as a reported adverse effect and two papers reported dizziness but no 24, 25 hypotension. It appears that dizziness does occur in a small proportion of patients but this seems unrelated to orthostatic hypotension. Adverse Effects Likely to Occur The most common adverse events reported for patients taking lurasidone (greater than 5% and at least twice the rate of placebo) were akathisia, nausea, parkinsonism, and 7, 12 somnolence. Dose-related adverse effects are akathisia, somnolence, and parkinsonism with doses higher than 80 mg associated with an increase in akathisia, parkinsonism, somnolence, and prolactin elevations without additional statistically significant clinical benefit. 12 Hyperprolactinaemia While lurasidone does cause prolactin elevation in significantly more patients than placebo, 7 a comparative study ranked this effect well below that caused by risperidone, paliperidone and haloperidol. 13 Extrapyramidal Side Effects Lurasidone shows a higher risk for akathisia compared to risperidone, olanzapine, and quetiapine. Lurasidone also appears to increase the risk of anxiety but not agitation. 26 Somnolence Despite its lack of H 1 effects, somnolence appears to be reported by patients. Lurasidone has been ranked amongst the least sedating antipsychotics but still more sedating than aripiprazole, iloperidone, sertindole, paliperidone and amisulpride. In Graylands Hospital Drug Bulletin April 2016 Vol 23 No.1 Page 3
4 terms of sedation it is comparable to risperidone, haloperidol and asenapine. 13 Patient Reviews Although highly unreliable, it can sometimes be instructive to scan comments made by patients on websites about new drugs. Most of the side effects discussed by patients are the usual akathisia, parkinsonism and sedation. However, a repeated theme is discussion of effects that appear to be aggression, irritability, activation or even a manic switch. This should not be surprising since the recent direction of research has been towards the antidepressant effects of lurasidone. Prescribers should be mindful of the risks of prescribing an antipsychotic that can have antidepressant effects to patients at risk of activation. Pregnancy and Lactation Lurasidone is a category B1 drug in pregnancy i.e. no foetal toxicities have been observed in animal studies. 27 However exposure to lurasidone in the third trimester has been reported to increase the incidence of extrapyramidal and withdrawal symptoms in newborns. 27 Lurasidone does partition into breast milk of rats, therefore, lurasidone is not recommended to be used during breastfeeding. 27 Dosage The efficacy of lurasidone has been established at doses of 40, 80, 120 and 160 mg/day. The recommended starting dose is 40 mg once daily. Initial dose titration is not required. Patients should be treated with the lowest effective dose that provides optimal clinical response and tolerability, which is expected to be 40 mg or 80 mg once daily for most patients. Dose increases should be based on physician judgement and observed clinical response. In the six week controlled trials, there was no suggestion of added benefit with the 120 mg/day dose compared to 40 and 80 mg/day. In the pooled analyses, no added benefit occurred at 160 mg/day compared to lower doses. Doses above 80 mg may be considered for certain patients based on individual clinical judgement. The maximum recommended dose is 160 mg/day. 2 It is possible that evening dose administration is associated with more favourable tolerability overall relative to morning dosing. 19 Efficacy There is now a considerable body of evidence demonstrating superiority over placebo of lurasidone in the treatment of schizophrenia and depression in bipolar disorder. Non-inferiority has also been demonstrated against most of the current treatments. Placebo controlled trials have demonstrated efficacy for lurasidone in the treatment of schizophrenia 15, 28 Lurasidone has also been shown to be as effective as olanzapine 29 and quetiapine. 30 Comparable efficacy rates have been seen with risperidone although in one study all-cause discontinuation rates were higher with lurasidone. 25 Lurasidone significantly improved depressive symptoms compared with placebo in patients with major depressive disorder associated with subthreshold hypomanic symptoms 18, 24 (mixed features). An open-label, uncontrolled extension study demonstrated the safety and tolerability of lurasidone during 6 months of treatment for bipolar disorder, both as monotherapy and adjunctive with lithium or valproate. 16 Treatment with lurasidone has been associated with sustained improvement in depressive symptoms, and in patient-rated measures of quality of life and functioning. Lurasidone monotherapy has been shown to be comparable in terms of efficacy to the combination of olanzapine and fluoxetine, and superior to quetiapine, lithium or lamotrigine. 31 Cognitive enhancement from lurasidone has been linked with its strong affinity to 5-HT 7 32, 33 receptors. It has also been suggested that the concomitant inhibition of dopamine D2 and D4 receptors could induce cognitive impairment, and the lack of dopamine D4 receptor antagonism by lurasidone may contribute to its cognitive-enhancing effect. 34 Graylands Hospital Drug Bulletin April 2016 Vol 23 No.1 Page 4
5 Place in Therapy From the data published so far, lurasidone appears to be as effective as currently available antipsychotics in the treatment of schizophrenia with some advantages in side effect profile. It appears less likely to cause metabolic and cardiac effects but more likely to cause EPSE compared to other second generation antipsychotics. Although it is only licenced in Australia for the treatment of schizophrenia, lurasidone has been shown to be effective in the acute phase of depressive disorders associated with bipolar disorder, including depressive disorders with mixed features. Unlike most other antipsychotics, cognitive enhancement and antidepressant effects have been attributed to lurasidone. TGA changes to medication names The Therapeutic Goods Administration (TGA) has announced changes to the names of some medicines in Australia, occurring from April The intent is to better align with names used internationally. A complete list of medicines affected is available on the TGA website. Other countries such as the United Kingdom and New Zealand have already updated these names. There will be a four year transition period in which these changes will occur. The labelling and packaging of existing products will need to change over this period. The changes to psychotropic drugs are summarised below: Old Name New Name Overdose Two case reports of overdose with lurasidone were found, one patient ingesting 560mg and the other 1360mg. In both cases the patients recovered without any significant medical sequelae. The larger overdose was associated with mild hypertension and a single raised TSH result. 35 Availability Latuda film-coated tablets are intended for oral administration only. In Australia lurasidone is available in 40 mg (equivalent to mg lurasidone), or 80 mg (equivalent to mg lurasidone). In other countries a 20mg tablet is also available. 6 Conversations with Servier indicate that the tablets are recommended to be swallowed whole to mask the bitter taste. This Drug Bulletin was written by Darren Schwartz and was reviewed by Dr Joseph Lee and the Graylands Pharmacy Department Benzhexol Dothiepin Phenobarbitone Phenobarbitone sodium Benztropine mesylate Dexamphetamine sulfate Flupenthixol decanoate Pericyazine trihexyphenidyl (benzhexol) dosulepin (dothiepin) phenobarbital (phenobarbitone) phenobarbital (phenobarbitone) sodium benzatropine mesilate dexamfetamine sulfate flupentixol decanoate periciazine Comments are welcome at the address: DrugInformation.Graylands@health.wa.gov.au Graylands Hospital Drug Bulletin April 2016 Vol 23 No.1 Page 5
6 References 1. Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clinical schizophrenia & related psychoses 2011 Jan;4(4): Macaluso M, Kazanchi H, Preskorn SH. How the pharmacokinetics and receptorbinding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia. Expert opinion on drug metabolism & toxicology 2015;11(8): Potkin SG, Keator DB, Kesler-West ML, et al. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS spectrums 2014 Apr;19(2): Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5- hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. The Journal of pharmacology and experimental therapeutics 2010 Jul;334(1): Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert opinion on investigational drugs 2009 Nov;18(11): Lurasidone Product Information. In: Laboratories S, ed. Version 4c ed; Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved secondgeneration antipsychotic. International journal of clinical practice 2011 Feb;65(2): Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. Lurasidone (SM ), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007 Oct 31;572(2-3): Latuda, INN-lurasidone - Europa. European Medicines Agency; Lurasidone US Approval. 11. UK Prescribing information LATUDA. In: Pharmaceuticals S, ed. Europe; Risbood V, Lee JR, Roche-Desilets J, Fuller MA. Lurasidone: an atypical antipsychotic for schizophrenia. The Annals of pharmacotherapy 2012 Jul- Aug;46(7-8): Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013 Sep 14;382(9896): Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A. Weight change during longterm treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. International clinical psychopharmacology 2015 Nov;30(6): Tandon R, Cucchiaro J, Phillips D, et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of psychopharmacology 2016 Jan;30(1): Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A. LURASIDONE IN THE LONG TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24 WEEK OPEN LABEL EXTENSION STUDY. Depression and anxiety Sanford M, Dhillon S. Lurasidone: a review of its use in adult patients with bipolar I depression. CNS drugs 2015 Mar;29(3): McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. The Journal of clinical psychiatry 2015 Apr;76(4): Harvey PD. The clinical utility of lurasidone in schizophrenia: patient considerations. Neuropsychiatric disease and treatment 2015;11: Franklin R, Zorowitz S, Corse AK, Widge AS, Deckersbach T. Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatric disease and treatment 2015;11: Findlay LJ, El-Mallakh P, El-Mallakh RS. Management of bipolar I depression: clinical utility of lurasidone. Therapeutics and clinical risk management 2015;11: Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert review of clinical pharmacology 2013 Jan;6(1): Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatric disease and treatment 2012;8: Graylands Hospital Drug Bulletin April 2016 Vol 23 No.1 Page 6
7 24. Suppes T, Silva R, Cucchiaro J, et al. Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study. The American journal of psychiatry 2015 Nov 10:appiajp Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. International clinical psychopharmacology 2012 May;27(3): Thomas JE, Caballero J, Harrington CA. The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis. Curr Neuropharmacol 2015;13(5): Team APW. Lurasidone Loebel A, Cucchiaro J, Silva R, et al. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebocontrolled studies. European psychiatry : the journal of the Association of European Psychiatrists 2015 Jan;30(1): Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, doubleblind, placebo- and olanzapine-controlled study. The American journal of psychiatry 2011 Sep;168(9): Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, doubleblind, placebo- and active-controlled trial. Schizophrenia research 2013 Apr;145(1-3): Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments metaanalysis. Acta psychiatrica Scandinavica 2014 Dec;130(6): Sumiyoshi T, Higuchi Y, Uehara T. Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia. Frontiers in behavioral neuroscience 2013;7: Meltzer HY, Rajagopal L, Huang M, Oyamada Y, Kwon S, Horiguchi M. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 2013 Nov;16(10): Murai T, Nakako T, Ikeda K, Ikejiri M, Ishiyama T, Taiji M. Lack of dopamine D4 receptor affinity contributes to the procognitive effect of lurasidone. Behavioural brain research 2014 Mar 15;261: Molnar GP, Grimsich LC, Catalano G, Catalano MC. Acute lurasidone overdose. Journal of clinical psychopharmacology 2014 Dec;34(6): Graylands Hospital Drug Bulletin April 2016 Vol 23 No.1 Page 7
Lurasidone: A New Antipsychotic For Schizophrenia. Objectives. Introduction. Pharmacology/Pharmacokinetics. Mechanism of Action. Mechanism of Action
Lurasidone: A New Antipsychotic For Schizophrenia Theodore Pikoulas, PharmD PGY2 Psychiatric Pharmacy Resident Louis Stokes Cleveland VAMC Objectives Review the pharmacology and the pharmacokinetics Identify
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More information) and serotonin Type 2 (5-HT 2A
Latuda (lurasidone HCl) Fact Sheet Schizophrenia FREQUENTLY ASKED QUESTIONS What type of patient with schizophrenia is appropriate for LATUDA? LATUDA is an atypical antipsychotic agent indicated for the
More informationAntipsychotics: The Essentials. Module 5: A Primer on Selected Antipsychotics
Antipsychotics: The Essentials Module 5: A Primer on Selected Antipsychotics Slide 1 Recently approved antipsychotics Iloperidone (Fanapt) - 2009 Asenapine (Saphris, Sycrest) - 2009 Lurasidone (Latuda)
More informationLURASIDONE. THERAPEUTICS Brands LATUDA see index for additional brand names
LURASIDONE THERAPEUTICS Brands LATUDA see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin receptor antagonist (DS-RAn) Atypical antipsychotic (serotonin-dopamine
More informationDosing & Administration
Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an
More informationNew Medications in Early Psychosis
New Medications in Early Psychosis Jean Starling Department of Psychological Medicine, the Children s Hospital at Westmead Department of Psychological Medicine and Department of Paediatrics and Child Health,
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationTHIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes
THIOTHIXENE THERAPEUTICS Brands Navane see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, thioxanthene, dopamine 2 antagonist) Commonly Prescribed for (bold
More informationMedication Audit Checklist- Antipsychotics - Atypical
Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,
More informationPERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes
PERPHENAZINE THERAPEUTICS Brands Trilafon see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine receptor antagonist (D-RAn) Conventional antipsychotic (neuroleptic,
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationBLONANSERIN. THERAPEUTICS Brands Lonasen see index for additional brand names
BLONANSERIN THERAPEUTICS Brands Lonasen see index for additional brand names Generic? No Class Atypical antipsychotic (serotonin dopamine antagonist; second-generation antipsychotic; also a potential mood
More informationASENAPINE. THERAPEUTICS Brands SAPHRIS see index for additional brand names
ASENAPINE THERAPEUTICS Brands SAPHRIS see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin, norepinephrine receptor antagonist (DSN-RAn) Atypical
More informationasenapine 5mg, 10mg sublingual tablet (Sycrest ) SMC No. (762/12) Lundbeck Ltd
asenapine 5mg, 10mg sublingual tablet (Sycrest ) SMC No. (762/12) Lundbeck Ltd 10 February 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More informationChapter 161 Antipsychotics
Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in
More informationPERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes
PERPHENAZINE THERAPEUTICS Brands Trilafon see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist, antiemetic) Commonly Prescribed
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More informationTRIFLUOPERAZINE. THERAPEUTICS Brands Stelazine see index for additional brand names
TRIFLUOPERAZINE THERAPEUTICS Brands Stelazine see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine receptor antagonist (D-RAn) Conventional antipsychotic (neuroleptic,
More informationSlide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts
Slide 1 Risperidone Binding Profile (high affinity for D2 receptors) a 1 antagonist a 2 antagonist Slide 2 Risperidone Prescribing Facts 2 8 mg/day for acute psychosis and bipolar disorder 0.5-2 mg /day
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationSafety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents
Pediatr Drugs (2013) 15:217 233 DOI 10.1007/s40272-013-0024-6 REVIEW ARTICLE Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents Silvio Caccia Published online: 16 April
More informationObjectives. DSM-V Changes: Elimination of Multiaxial Diagnostic System
Conflicts of Interest I have no conflicts to disclose. 2014 Updates to the Updates in Pharmacotherapy Webinar Psychiatry Updates for Pharmacotherapy Specialists Jacintha S. Cauffield, Pharm.D., BCPS Associate
More informationHearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds
Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 November 2011 SYCREST 5 mg, sublingual tablet B/60 (CIP code: 415 241-6) B/100 (CIP code: 579 353-1) SYCREST 10
More informationSTEP THERAPY CRITERIA
DRUG CLASS PRODUCTS) BRAND NAME (BRAND ONLY) (generic) STEP THERAPY CRITERIA ATYPICAL ANTIPSYCHOTICS (BRAND ONLY ABILIFY (AL TABLET & AL SOLUTION ONLY) (aripiprazole) FANAPT (BRAND ONLY) (iloperidone)
More informationWhat's New in the World of Antipsychotics?
Handout for the Neuroscience Education Institute (NEI) online activity: What's New in the World of Antipsychotics? (page 7 in syllabus) Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry
More informationInteractions between Antiepileptics and Second- Generation Antipsychotics
University of Kentucky UKnowledge Psychiatry Faculty Publications Psychiatry 3-2012 Interactions between Antiepileptics and Second- Generation Antipsychotics Jose de Leon University of Kentucky, jdeleon@uky.edu
More informationIs Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Lurasidone more safe and effective
More informationQUETIAPINE. THERAPEUTICS Brands Seroquel Seroquel XR see index for additional brand names. Generic? Yes
QUETIAPINE THERAPEUTICS Brands Seroquel Seroquel XR see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine, serotonin multimodal (DS-MM) Atypical antipsychotic
More informationLOXAPINE. THERAPEUTICS Brands Loxitane Adasuve (Staccato loxapine, inhaled loxapine) see index for additional brand names. Generic?
LOXAPINE THERAPEUTICS Brands Loxitane Adasuve (Staccato loxapine, inhaled loxapine) see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine and serotonin receptor
More informationSlide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics
Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second
More informationClozapine Case 1 The Relevance of CYP Jose de Leon, MD
Clozapine Case 1 The Relevance of CYP 12-18-15 Jose de Leon, MD 1. Clozapine Case 1 J Clin Psychiatry 1996;57:175-176 http://www.ncbi.nlm.nih.gov/pubmed/8601555 Educational Objectives At the conclusion
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.59 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at the
More informationQUEPINE XR PRODUCT INFORMATION. Name of the medicine. Description. Pharmacology
QUEPINE XR PRODUCT INFORMATION Name of the medicine Quetiapine fumarate. The chemical name is Bis[2-(2-[4-(dibenzo[b,f][1,4]-thiazepin-11-yl)piperazin- 1-yl] ethoxy) ethanol] fumarate. Its structural formula
More informationPALIPERIDONE. THERAPEUTICS Brands INVEGA INVEGA SUSTENNA INVEGA TRINZA see index for additional brand names
PALIPERIDONE THERAPEUTICS Brands INVEGA INVEGA SUSTENNA INVEGA TRINZA see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin receptor antagonist (DS-RAn)
More informationILOPERIDONE. THERAPEUTICS Brands FANAPT see index for additional brand names. Generic? No
ILOPERIDONE THERAPEUTICS Brands FANAPT see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine and serotonin receptor antagonist (DS-RAn) Atypical antipsychotic
More informationARIPIPRAZOLE. THERAPEUTICS Brands Abilify Abilify Maintena Aristada see index for additional brand names. Generic? Yes
ARIPIPRAZOLE THERAPEUTICS Brands Abilify Abilify Maintena Aristada see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine, serotonin receptor partial agonist
More informationConcomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of LATUDA (2.5, 7.1).
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (lurasidone hydrochloride) tablets,
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:
0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:
More informationPerinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs
Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2015) Principal Author: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationComparison of Atypical Antipsychotics
PL Detail-Document #281006 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2012 Comparison of
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationKelly Godecke, MD Department of Psychiatry University of Utah
Kelly Godecke, MD Department of Psychiatry University of Utah Epidemiology and Impact -module 2 session 1 overview of mood disorders Diagnostic Criteria of Bipolar Disorders Medications Used in Bipolar
More informationCHLORPROMAZINE. THERAPEUTICS Brands Thorazine see index for additional brand names
CHLORPROMAZINE THERAPEUTICS Brands Thorazine see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine and serotonin receptor antagonist (DS-RAn) Conventional antipsychotic
More informationTreat Schizophrenia Schizoaffective disorder Bipolar disorder Psychotic depression Off-label uses Insomnia Tics Delirium Stuttering
Robert M. Millay RN MSN Ed Professor, Napa Valley College Psychiatric Technician Programs Copyright 2015, 2011, 2007, 2003, 1999, 1995, 1991 by Mosby, an imprint of Elsevier Inc. Treat Schizophrenia Schizoaffective
More informationIn August 2009, the FDA approved asenapine
For mass reproduction, content licensing and permissions contact Dowden Health Media. p Asenapine for schizophrenia and bipolar I disorder Jana Lincoln, MD, and Sheldon Preskorn, MD In August 2009, the
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationAggression (Severe) in Children under Age 6
Aggression (Severe) in Children under Age 6 Level 0 Comprehensive diagnostic assessments. Refer to Principles of Practice on page 6. Evaluate and treat comorbid conditions (i.e. medical, other psychiatric
More informationPage 1 of RECENT MAJOR CHANGES Warnings and Precautions, Falls (5.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use QUETIAPINE FUMARATE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationSeroquel XR. quetiapine fumarate APPROVED PRODUCT INFORMATION
Seroquel XR quetiapine fumarate APPROVED PRODUCT INFORMATION NAME OF THE MEDICINE Quetiapine fumarate Chemical Name: Bis[2-(2-[4-(dibenzo[b,f][1,4]-thiazepin-11-yl)piperazin-1-yl] ethoxy) ethanol] fumarate.
More informationANTIPSYCHOTIC POLYPHARMACY
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTIPSYCHOTIC POLYPHARMACY RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UWMC GENERAL DISCLOSURES The University
More informationConcomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of LATUDA (2.6, 7.1).
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (lurasidone hydrochloride) tablets,
More informationZIPRASIDONE. THERAPEUTICS Brands Geodon see index for additional brand names
ZIPRASIDONE THERAPEUTICS Brands Geodon see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine and serotonin receptor antagonist (DS_RAn) Atypical antipsychotic
More informationOLANZAPINE tablets USP, for oral use OLANZAPINE orally disintegrating tablets USP, for oral use Initial U.S. Approval: 1996
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OLANZAPINE safely and effectively. See full prescribing information for OLANZAPINE. OLANZAPINE tablets
More informationPRODUCT INFORMATION TEVATIAPINE XR (quetiapine fumarate)
PRODUCT INFORMATION TEVATIAPINE XR (quetiapine fumarate) NAME OF THE MEDICINE Active ingredient: Quetiapine fumarate Chemical Name: Bis[2-(2-[4-(dibenzo[b,f][1,4]-thiazepin-11-yl)piperazin-1-yl] ethoxy)
More informationElements for a Public Summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Schizophrenia Schizophrenia is a mental disorder often characterized by abnormal social behaviour and failure to recognize what
More informationSTARTING PATIENTS ON. AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia.
STARTING PATIENTS ON AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia. Indication: AA-CLOZAPINE (clozapine) is indicated in the management
More informationPractical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current Clinical Guidelines
SECOND-GENERATION ANTIPSYCHOTICS IN BIPOLAR DISORDER Practical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current s Flavio Guzman, MD Editor Psychopharmacology Institute
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationQuetiapine (SEROQUEL XR), extended-release tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg
Quetiapine Seroquel XR 50 mg, 150mg, 200mg, 300mg and 400mg Extended Release Tablet 0500960/2 Anti-psychotic 1. NAME OF THE MEDICINAL PRODUCT Quetiapine (SEROQUEL XR), extended-release tablets, 50 mg,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationPotential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole
University of Wollongong Research Online Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health 2010 Potential control of antipsychotic-induced hyperprolactinemia and
More informationSummary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole)
EMA/370707/2016 Summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma, which details the
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationValproate Case 3: Formulations Jose de Leon, MD
Valproate Case 3: Formulations 2-12-16 Jose de Leon, MD 3.Valproate Case 3 Described in J Clin Psychiatry 2004;65:724-5 http://www.ncbi.nlm.nih.gov/pubmed/15163266 Pharmacological explanation provided
More informationFULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SEROQUEL XR safely and effectively. See full prescribing information for SEROQUEL XR. SEROQUEL XR
More informationSP.236 / ESG.SP236 Exploring Pharmacology Spring 2009
MIT OpenCourseWare http://ocw.mit.edu SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Atypical (2
More informationFAQ - ARIPIPRAZOLE Educational materials for the Healthcare profesionals
FAQ - ARIPIPRAZOLE Educational materials for the Healthcare profesionals Aripiprazole Dr. Reddy's 5, 10, 15 and 30 mg film-coated tablets Aripiprazole is indicated for the treatment up to 12 weeks of moderate-to-severe
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationRoles of primary care physicians in managing bipolar disorders in adults
CPG UPDATE Roles of primary care physicians in managing bipolar disorders in adults Awaluddin A, Jali N, Bahari R, Jamil Z, Haron N on behalf of Development Group Clinical Practice Guidelines Management
More information10-14 SEROQUEL ASTRAZENECA
10-14 SEROQUEL ASTRAZENECA quetiapine fumarate Trademark Presentation - 25 mg tablet: round, 6 mm, peach coloured, biconvex, film-coated tablet containing quetiapine fumarate delivering a dose of 25 mg
More informationThe antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in
Antipsychotic Drugs The antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in other psychotic and manic states.
More informationSIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product.
SIFROL â Composition 1 tablet contains 0.088, 0.18 & 0.7 mg (S) 2 amino 4,5,6,7-tetrahydro-6-propylamino-benzothiazole (= pramipexole base) equivalent to 0.125, 0.25 & 1 mg of pramipexole dihydrochloride
More informationLemilvo Tablets (aripiprazole)
Lemilvo Tablets (aripiprazole) Healthcare Professional Frequently Asked Questions (FAQ) Brochure Bipolar I Disorder in Adolescents Lemilvo (aripiprazole) is indicated for the treatment up to 12 weeks of
More informationQuetiapine Case 2 Therapeutic Drug Monitoring Jose de Leon, MD
Quetiapine Case 2 Therapeutic Drug Monitoring 1-27-16 Jose de Leon, MD 2. Quetiapine Case Therapeutic Drug Monitoring (unpublished) Educational Objectives At the conclusion of this presentation, the participant
More informationScottish Medicines Consortium
Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish
More informationCYAMEMAZINE. THERAPEUTICS Brands Tercian see index for additional brand names
CYAMEMAZINE THERAPEUTICS Brands Tercian see index for additional brand names Generic? Not in the USA Class Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist, serotonin dopamine
More informationDosing & Administration
Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants.
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationCariprazine is a newly approved
Cariprazine for schizophrenia and bipolar I disorder Gregory Mattingly, MD, and Richard Anderson, MD, PhD Cariprazine is a newly approved (September 2015) dopamine D3/D2 receptor partial agonist with higher
More informationThings You Might Not Know About Psychotropic Medications But Wish You Did
Things You Might Not Know About Psychotropic Medications But Wish You Did John E. Dunne, MD December 3, 2016 PAL Conference Conflicts of Interest None to report I am employed by Seattle Children s and
More informationPOLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 2012 PSYCHOPHARMACOLOGY SERIES. Guna Kanniah Waikato Hospital
POLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 212 PSYCHOPHARMACOLOGY SERIES Guna Kanniah Waikato Hospital POLYPHARMACY FIVE REASONS FOR POLYPHARMACY 1. To treat a concomitant disorder 2. To treat an
More informationCIZOREST Tablets (Amisulpride)
Published on: 2 Dec 2015 CIZOREST Tablets (Amisulpride) Composition CIZOREST 50mg Tablets Each film-coated tablet contains: Amisulpride..50 mg CIZOREST 100mg Tablets Each film-coated tablet contains: Amisulpride..100
More informationN e w s R e l e a s e
Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700 N e w s R e l e a s e Contact: Patrick Gaffey Senior Director, Corporate Communications Sunovion Pharmaceuticals
More informationin the formulation. (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
More informationStudy Design Results from PREVAIL 1 and PREVAIL 2
April 24, 2012 Company name: Dainippon Sumitomo Pharma Co., Ltd Representative: Masayo Tada, President (Securities Code: 4506, 1st Section of TSE and OSE) Contact: Atsuko Higuchi, Director Corporate Communication
More information